Arbutus Biopharma Corporation I9DN.F Stock
Arbutus Biopharma Corporation Price Chart
Arbutus Biopharma Corporation I9DN.F Financial and Trading Overview
Arbutus Biopharma Corporation stock price | 2.52 EUR |
Previous Close | 2.24 EUR |
Open | 2.17 EUR |
Bid | 2.18 EUR x 100000 |
Ask | 2.27 EUR x 100000 |
Day's Range | 2.17 - 2.17 EUR |
52 Week Range | 1.9 - 2.94 EUR |
Volume | 3K EUR |
Avg. Volume | 293 EUR |
Market Cap | 364.1M EUR |
Beta (5Y Monthly) | 2.249647 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.41 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.9 EUR |
I9DN.F Valuation Measures
Enterprise Value | 225.87M EUR |
Trailing P/E | N/A |
Forward P/E | -2.7468355 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 10.991762 |
Price/Book (mrq) | 2.4885323 |
Enterprise Value/Revenue | 6.819 |
Enterprise Value/EBITDA | -3.311 |
Trading Information
Arbutus Biopharma Corporation Stock Price History
Beta (5Y Monthly) | 2.249647 |
52-Week Change | -8.74% |
S&P500 52-Week Change | 20.43% |
52 Week High | 2.94 EUR |
52 Week Low | 1.9 EUR |
50-Day Moving Average | 2.44 EUR |
200-Day Moving Average | 2.39 EUR |
I9DN.F Share Statistics
Avg. Volume (3 month) | 293 EUR |
Avg. Daily Volume (10-Days) | 20 EUR |
Shares Outstanding | 166.13M |
Float | 124.36M |
Short Ratio | N/A |
% Held by Insiders | 25.21% |
% Held by Institutions | 32.79% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -211.41% |
Operating Margin (ttm) | -210.082% |
Gross Margin | -154.25% |
EBITDA Margin | -205.95% |
Management Effectiveness
Return on Assets (ttm) | -20.31% |
Return on Equity (ttm) | -45.21% |
Income Statement
Revenue (ttm) | 33.13M EUR |
Revenue Per Share (ttm) | 0.22 EUR |
Quarterly Revenue Growth (yoy) | -46.80% |
Gross Profit (ttm) | -45389000 EUR |
EBITDA | -68223000 EUR |
Net Income Avi to Common (ttm) | -70030000 EUR |
Diluted EPS (ttm) | -0.42 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 146.73M EUR |
Total Cash Per Share (mrq) | 0.88 EUR |
Total Debt (mrq) | 2.12M EUR |
Total Debt/Equity (mrq) | 1.47 EUR |
Current Ratio (mrq) | 6.077 |
Book Value Per Share (mrq) | 0.872 |
Cash Flow Statement
Operating Cash Flow (ttm) | -83276000 EUR |
Levered Free Cash Flow (ttm) | -42157000 EUR |
Profile of Arbutus Biopharma Corporation
Country | Germany |
State | PA |
City | Warminster |
Address | 701 Veterans Circle |
ZIP | 18974 |
Phone | 267 469 0914 |
Website | https://www.arbutusbio.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 96 |
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Q&A For Arbutus Biopharma Corporation Stock
What is a current I9DN.F stock price?
Arbutus Biopharma Corporation I9DN.F stock price today per share is 2.52 EUR.
How to purchase Arbutus Biopharma Corporation stock?
You can buy I9DN.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Arbutus Biopharma Corporation?
The stock symbol or ticker of Arbutus Biopharma Corporation is I9DN.F.
Which industry does the Arbutus Biopharma Corporation company belong to?
The Arbutus Biopharma Corporation industry is Biotechnology.
How many shares does Arbutus Biopharma Corporation have in circulation?
The max supply of Arbutus Biopharma Corporation shares is 189.92M.
What is Arbutus Biopharma Corporation Price to Earnings Ratio (PE Ratio)?
Arbutus Biopharma Corporation PE Ratio is now.
What was Arbutus Biopharma Corporation earnings per share over the trailing 12 months (TTM)?
Arbutus Biopharma Corporation EPS is -0.41 EUR over the trailing 12 months.
Which sector does the Arbutus Biopharma Corporation company belong to?
The Arbutus Biopharma Corporation sector is Healthcare.